Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
about
The potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaDiffuse Large B Cell Lymphoma Cell Line U-2946: Model for MCL1 Inhibitor Testing.Knockdown of ST6Gal-I increases cisplatin sensitivity in cervical cancer cells.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.Venetoclax: First Global Approval.Survival control of malignant lymphocytes by anti-apoptotic MCL-1.The landscape of new drugs in lymphomaTargeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.Mcl-1 regulates reactive oxygen species via NOX4 during chemotherapy-induced senescence.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling.Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.Pathways and mechanisms of venetoclax resistance.Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
P2860
Q28075504-D82C8292-3CB0-424A-90F8-BE9871C7A536Q36210487-C2AAD480-486A-42FE-A06C-2F13A506C474Q36226902-B94D9EF6-6B6D-478F-A676-CEFE92481195Q37521403-EB077EFF-CEE2-4959-BE96-2E106C47BC2BQ38637652-B8DEDB9B-A79E-4D5C-BA70-C6D60662BAA2Q38722012-80B03F74-53F7-4519-A973-29D5EAA8F7CDQ38739256-575CE6BF-D8AD-4A36-BE08-4C7B4148A208Q38853500-9E37743D-AC26-4CDD-8DE9-76782442DB9FQ38914858-548F83ED-806A-4ECD-AC8C-27F351E1D7D4Q39061630-9BE5D95B-58CC-49CC-91EF-12591BF5A11DQ39267135-AEA2E5DA-E7D2-48B7-A351-E1DBA8154FC1Q41070355-9849B138-A16D-4847-BAA4-0CB7E7B82088Q42254401-27A44E4D-087C-4A6A-8A60-0F967386EB3CQ46370948-FF464636-5334-4F8C-8487-34C58C9EB0D3Q46640442-BE08B348-6CC6-4F19-A5D2-C453117E2C12Q47130049-365DC85B-002B-457E-945F-E31C8D37A26EQ47567993-AB224BD8-D4CC-4032-9B82-79040BEC76B6Q48316021-AA87ABED-3643-401E-9207-24B85E04723FQ50017171-23A735C5-EEBB-42D6-AF9A-230DDE76FE13Q51160342-85E0134D-A0A6-432F-BED4-6625D6667278Q51280033-E211AF95-B35D-42EF-B0FE-D59BEE83A34DQ54985966-F95C9D1D-EFE6-43D4-919F-D5ED9086A92F
P2860
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@ast
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@en
type
label
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@ast
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@en
prefLabel
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@ast
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@en
P2093
P2860
P356
P1433
P1476
Loss in MCL-1 function sensiti ...... inhibitor venetoclax (ABT-199)
@en
P2093
A J Souers
D C Phillips
E Litvinovich
J D Leverson
L Roberts-Rapp
P2860
P2888
P356
10.1038/BCJ.2015.88
P577
2015-11-13T00:00:00Z